Cancer Research and Treatment

Case Report

PTEN Mutation Identified in Patient Diagnosed with Simultaneous Multiple Cancers: Hye Sung Won, Eun Deok Chang, Sae Jung Na, In Yong Whang, Dong Soo Lee, Sun Hyong You, Yong Seok Kim, Jeong Soo Kim; Cancer Res Treat. 2019;51(1):402-407. Published online February 27, 2018; DOI: https://doi.org/10.4143/crt.2017.579

PTEN hamartoma tumor syndrome is a spectrum of disorders characterized by unique phenotypic features including multiple hamartomas caused by mutations of the tumor suppressor gene PTEN. Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome are representative diseases, and both have several common clinical features and differences. Because PTEN mutations are associated with an increased risk of malignancy including breast, thyroid, endometrial, and renal cancers, cancer surveillance is an important element of disease management. We report a germline mutation of the PTEN (c.723dupT, exon 7) identified in a young woman with a simultaneous occurrence of breast cancer, dermatofibrosarcoma protuberans, and follicular neoplasm. This case suggests that it is critical for clinicians to recognize the phenotypic features associated with these syndromes to accurately diagnose them and provide preventive care.

Citations

Citations to this article as recorded by

Synchronous and metachronous thyroid cancer, breast cancer, and melanoma in a premenopausal patient with Cowden syndrome
Belinda Asare, Babita Panigrahi
Radiology Case Reports.2023; 18(5): 1918. CrossRef
Molecular Action of Herbal Antioxidants in Regulation of Cancer Growth: Scope for Novel Anticancer Drugs
Manjula Vinayak
Nutrition and Cancer.2018; 70(8): 1199. CrossRef

8,425 View
277 Download
2 Web of Science
2 Crossref

Original Article

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years: Ji Hyung Hong, Kyung Sun Ha, Yun Hwa Jung, Hye Sung Won, Ho Jung An, Guk Jin Lee, Donghoon Kang, Ji Chan Park, Sarah Park, Jae Ho Byun, Young Jin Suh, Jeong Soo Kim, Woo Chan Park, Sang Seol Jung, Il Young Park, Su-Mi Chung, In Sook Woo; Cancer Res Treat. 2016;48(4):1389-1398. Published online April 11, 2016; DOI: https://doi.org/10.4143/crt.2015.410

Abstract PDF PubReader ePub

Purpose
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.
Materials and Methods
Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.
Results
Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.
Conclusion
Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.

Citations

Citations to this article as recorded by

Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer
Yaping Huang, Chengjie Ke, Jiaqin Cai, Xiaoxia Wei, Maohua Chen, Hong Sun
Breast Cancer.2024; 31(5): 917. CrossRef
Cáncer de mama en el varón: estudio multicéntrico en Aragón durante 27 años
Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
Cirugía Española.2024; 102(10): 524. CrossRef
Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival
Vlad Bogdan Varzaru, Diana-Maria Anastasiu-Popov, Anca-Elena Eftenoiu, Roxana Popescu, Daliborca Cristina Vlad, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, Daniela Puscasiu, Ionut Marcel Cobec
Cancers.2024; 16(17): 3049. CrossRef
Male breast cancer: A multicenter study in Aragon over 27 years
Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
Cirugía Española (English Edition).2024; 102(10): 524. CrossRef
Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran
Mahboobeh Asgharian, Dariush Moslemi, Hossein-Ali Nikbakht, Mohammad-Ali Jahani, Ali Bijani, Hakimeh Mehdizadeh
Annals of Medicine & Surgery.2024; 86(10): 5756. CrossRef
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S
Cancer Research and Treatment.2023; 55(1): 123. CrossRef
Clinicopathological features and correlation analysis of male breast cancer
Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong
Medicine.2023; 102(30): e34408. CrossRef
Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population‐based observational study
Wentong Fang, Yue Huang, Xu Han, Jinghui Peng, Mingjie Zheng
Cancer Medicine.2022; 11(3): 764. CrossRef
Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan
Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga
Breast Cancer Research and Treatment.2021; 186(3): 731. CrossRef
Ulcerated Nipple Nodule, Clinicopathologic Challenge: Answer
Ahmad Adel, Mona R. E. Abdel-Halim, Yosra Abdel-Galeil
The American Journal of Dermatopathology.2021; 43(6): 466. CrossRef
Genetic Landscape of Male Breast Cancer
Fernando Augusto Batista Campos, Etienne Rouleau, Giovana Tardin Torrezan, Dirce Maria Carraro, José Claudio Casali da Rocha, Higor Kassouf Mantovani, Leonardo Roberto da Silva, Cynthia Aparecida Bueno de Toledo Osório, Solange Moraes Sanches, Sandrine M.
Cancers.2021; 13(14): 3535. CrossRef
Treatment of male breast cancer: meta-analysis of real-world evidence
A. P. Lin, T.-W. Huang, K.-W. Tam
British Journal of Surgery.2021; 108(9): 1034. CrossRef
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
Ana D. Pinzón-García, Ruben Sinisterra, Maria Cortes, Fredy Mesa, Sandra Ramírez-Clavijo
PeerJ.2021; 9: e12124. CrossRef
Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group
Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee
Journal of Breast Cancer.2021; 24(6): 561. CrossRef
Meme Kanseri Cerrahisi Sonrası Lenfödem ve Uçak Seyahati
Aysel GÜL, Dilek AYGİN
İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2021; (15): 669. CrossRef
Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up
F. Pellini, S. Mirandola, E. Granuzzo, S. Urbani, G. Piccinni Leopardi, G. P. Pollini
Journal of Oncology.2020; 2020: 1. CrossRef
Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry
Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee
Cancer Research and Treatment.2020; 52(3): 739. CrossRef
The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population‐based observational study
Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Shui Wang, Wenbin Zhou
Cancer.2020; 126(S16): 3830. CrossRef
Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?
Tobias Forster, Clara Köhler, Rami El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Jörg Heil, Andreas Schneeweiss, Jürgen Debus, Juliane Hörner-Rieber
Cancers.2020; 12(12): 3645. CrossRef
Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
Francesca Pellini, Eleonora Granuzzo, Silvia Urbani, Sara Mirandola, Marina Caldana, Davide Lombardi, Elena Fiorio, Marta Mandarà, Giovanni Paolo Pollini
Breast Care.2020; 15(1): 14. CrossRef
Ultrasonographic and Mammographic Findings of Male Breast Disease
Su Hong Kim, Young‐Seon Kim
Journal of Ultrasound in Medicine.2019; 38(1): 243. CrossRef
Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study
Paul Rogowski, Stephan Schönecker, Montserrat Pazos, Daniel Reitz, Michael Braun, Martin Pölcher, Claus Hanusch, Rachel Wuerstlein, Nadia Harbeck, Sven Mahner, Claus Belka, Stefanie Corradini
Strahlentherapie und Onkologie.2019; 195(4): 289. CrossRef
Survival analysis for male ductal and lobular breast cancer patients with different stages
Jizhao Wang, Yuchen Sun, Jingkun Qu, Huang Zuo, Xixi Zhao, Lin Liu, Jinteng Feng, Jiansheng Wang, Guangjian Zhang
Future Oncology.2019; 15(2): 167. CrossRef
Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016
Weigang Wang, Xiaoqin Xu, Baoguo Tian, Yan Wang, Lili Du, Ting Sun, Yanchun Shi, Xianwen Zhao, Yali Jia, Yanfeng Xi, Jiexian Jing
Journal of Investigative Medicine.2019; 67(3): 699. CrossRef
Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database
Jun Xie, Yao-Yu Ying, Bin Xu, Yan Li, Xian Zhang, Chong Li
Therapeutic Advances in Medical Oncology.2019;[Epub] CrossRef
Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry
So-Youn Jung, Kyu-Won Jung, Johyun Ha, Young-Joo Won, Young Ae Kim, Youngmee Kwon, Sun-Young Kong, Eun Sook Lee
Cancer Epidemiology, Biomarkers & Prevention.2019; 28(7): 1169. CrossRef
Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions
Raza S. Hoda, Ronald N. Arpin III, Ravi V. Gottumukkala, Kevin S. Hughes, Amy Ly, Elena F. Brachtel
Acta Cytologica.2019; 63(4): 319. CrossRef
The endocrinology of male breast cancer
Ian S Fentiman
Endocrine-Related Cancer.2018; 25(6): R365. CrossRef
Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas
Yanjun Hou, Harrison S Moosavi, Lai Wei, Anil V Parwani, Xiaoxian (Bill) Li, Zaibo Li
American Journal of Clinical Pathology.2018; 150(6): 491. CrossRef
Axillary lymph node metastasis as the first manifestation of male occult breast cancer
Xinyu Wang, Liwen Fan, Wenxing Yan, Qi Zhang, Shunchao Bao, Ying Wang, Xin Bao, Linlin Liu
Medicine.2018; 97(50): e13706. CrossRef
A review of estrogen receptor/androgen receptor genomics in male breast cancer
Tesa M Severson, Wilbert Zwart
Endocrine-Related Cancer.2017; 24(3): R27. CrossRef
Imaging the Male Breast
Shruthi Ram, Shadi Aminololama-Shakeri
Current Radiology Reports.2017;[Epub] CrossRef
Mammary gland tumors in a male Cocker Spaniel
Soon-Chan Kwon, Dae-Young Yoo, Minho Ko, Kwon-Young Lee, Ho-Hyun Kwak, In-Chul Park, In-Koo Hwang, Jung-Hoon Choi, Jin-Young Chung
Acta Veterinaria Scandinavica.2017;[Epub] CrossRef
Male occult breast cancer with axillary lymph node metastasis as the first manifestation
Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu
Medicine.2017; 96(51): e9312. CrossRef

14,033 View
246 Download
36 Web of Science
34 Crossref

Case Report

Pseudocirrhosis of Breast Cancer Metastases to the Liver Treated by Chemotherapy: Su Lim Lee, Eun Deok Chang, Sae Jung Na, Jeong Soo Kim, Ho Jung An, Yoon Ho Ko, Hye Sung Won; Cancer Res Treat. 2014;46(1):98-103. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.98

Abstract PDF PubReader ePub

Pseudocirrhosis refers to a condition that shows changes in hepatic contour that mimic cirrhosis radiographically in the absence of the typical histopathological findings of cirrhosis. This condition has been observed in patients with cancer metastatic to the liver, both in those who have undergone prior systemic chemotherapy and those who have not. Pseudocirrhosis may cause difficulty in interpretation of the response to chemotherapy and hepatic decompression and complication of portal hypertension have a negative effect on the prognosis. We report on a case of breast cancer with liver metastases that showed cirrhotic changes during disease progression. Progression of liver metastases was confirmed by F18 fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT). We also performed ultrasound-guided liver biopsy and confirmed tumor infiltration with severe desmoplastic fibrosis. This case suggests the pathogenesis of pseudocirrhosis through histopathological findings and the role of PET-CT in evaluation of the response to chemotherapy in patients with pseudocirrhosis.

Citations

Citations to this article as recorded by

Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature
Gal Sadlik, Redmond-Craig Anderson, Xiaomeng Lei, Steven Yong Cen, Vinay A. Duddalwar, Tse-Ling Fong
Digestive Diseases and Sciences.2024; 69(3): 1004. CrossRef
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study
Laura A. Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennifer Callan, Danielle Brandman, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, A. Jo Chien
Breast Cancer Research and Treatment.2023; 197(1): 137. CrossRef
Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives
Dione Lother, Marie Robert, Elliot Elwood, Sam Smith, Nina Tunariu, Stephen R.D. Johnston, Marina Parton, Basrull Bhaludin, Thomas Millard, Kate Downey, Bhupinder Sharma
Cancer Imaging.2023;[Epub] CrossRef
Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases
Kazuhide Takata, Ai Mogi, Ryo Yamauchi, Satoshi Shakado, Fumihito Hirai
Cureus.2022;[Epub] CrossRef
Liver Metastases: Correlation between Imaging Features and Pathomolecular Environments
Kumi Ozaki, Shohei Higuchi, Hirohiko Kimura, Toshifumi Gabata
RadioGraphics.2022; 42(7): 1994. CrossRef
Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices
Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu
The Oncologist.2022; 27(12): 1008. CrossRef
Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis
Rosanna Villani, Francesca Di Cosimo, Moris Sangineto, Antonino Davide Romano, Gaetano Serviddio
Scientific Reports.2022;[Epub] CrossRef
Pseudocirrhosis in Breast Cancer – Experience From an Academic Cancer Center
Dharmesh Gopalakrishnan, Ain Shajihan, Andrei S. Purysko, Jame Abraham
Frontiers in Oncology.2021;[Epub] CrossRef
Unveiling the unreal: Comprehensive imaging review of hepatic pseudolesions
Subramaniyan Ramanathan, Vineetha Raghu, Vivek Virmani, Adnan Sheikh, Mahmoud Al Heidous, SreeHarsha Tirumani
Clinical Imaging.2021; 80: 439. CrossRef
Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: A case report
Tomohito Shinoda, Toshiyuki Tanahashi, Takuji Sakuratani, Masato Ota, Seito Fujibayashi, Shunya Kiriyama, Keita Matsumoto, Kazunori Yawata, Yoshiyuki Sasaki, Shinji Osada, Makoto Yamada
Molecular and Clinical Oncology.2021;[Epub] CrossRef
Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis
Linda Calistri, Vieri Rastrelli, Cosimo Nardi, Davide Maraghelli, Sofia Vidali, Michele Pietragalla, Stefano Colagrande
World Journal of Gastroenterology.2021; 27(46): 7866. CrossRef
Clinical features of pseudocirrhosis in metastatic breast cancer
Caspian Oliai, Michael L. Douek, Caelainn Rhoane, Abhishek Bhutada, Phillip S. Ge, Bruce A. Runyon, Xiaoyan Wang, Sara A. Hurvitz
Breast Cancer Research and Treatment.2019; 177(2): 409. CrossRef
Seudocirrosis en cáncer de mama metastásico
Alba Hidalgo-Blanco, Maddi Aguirresarobe-Gil de San Vicente, Santi Aresti, Eduardo de Miguel, Jose Luis Cabriada-Nuno
Gastroenterología y Hepatología.2018; 41(2): 111. CrossRef
Pseudocirrhosis in metastatic breast cancer
Alba Hidalgo-Blanco, Maddi Aguirresarobe-Gil de San Vicente, Santi Aresti, Eduardo de Miguel, Jose Luis Cabriada-Nuno
Gastroenterología y Hepatología (English Edition).2018; 41(2): 111. CrossRef
Pseudocirrhosis after chemotherapy in breast cancer, case reports
Tomoyoshi Aoyagi, Kazuaki Takabe, Tamaki Tamanuki, Hisahiro Matsubara, Hiroshi Matsuzaki
Breast Cancer.2018; 25(5): 614. CrossRef
Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis
Julie C. Birch, Gaurav Khatri, Lori M. Watumull, Yull E. Arriaga, John R. Leyendecker
RadioGraphics.2018; 38(4): 1158. CrossRef
Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease
Barbara Geeroms, Gert De Hertogh, Ragna Vanslembrouck, Hans Wildiers, Frederik Nevens, Geert Maleux
Journal of Vascular and Interventional Radiology.2018; 29(12): 1713. CrossRef
Delineating Extramammary Findings at Breast MR Imaging
Yiming Gao, Opeyemi Ibidapo, Hildegard K. Toth, Linda Moy
RadioGraphics.2017; 37(1): 10. CrossRef
Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases
Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi
Molecular and Clinical Oncology.2017; 6(1): 63. CrossRef
Systemic treatment in breast cancer: a primer for radiologists
Aya Y. Michaels, Abhishek R. Keraliya, Sree Harsha Tirumani, Atul B. Shinagare, Nikhil H. Ramaiya
Insights into Imaging.2016; 7(1): 131. CrossRef
Causes of hepatic capsular retraction: a pictorial essay
Gary Xia Vern Tan, Rhian Miranda, Tom Sutherland
Insights into Imaging.2016; 7(6): 831. CrossRef
Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy
Seiichiro Mitani, Shigenori Kadowaki, Hiroya Taniguchi, Hisanori Muto, Kei Muro
Case Reports in Oncology.2016; 9(1): 106. CrossRef
Pseudocirrhosis: A Case Series and Literature Review
Abimbola Adike, Nina Karlin, Christine Menias, Elizabeth J. Carey
Case Reports in Gastroenterology.2016; 10(2): 381. CrossRef
Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective
Danny Ngo, Jemianne Bautista Jia, Christopher S. Green, Anjalie T. Gulati, Chandana Lall
Insights into Imaging.2015; 6(6): 665. CrossRef
Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer
Rui-Jun Ju, Xue-Tao Li, Ji-Feng Shi, Xiu-Ying Li, Meng-Ge Sun, Fan Zeng, Jia Zhou, Lei Liu, Cheng-Xiang Zhang, Wei-Yu Zhao, Wan-Liang Lu
Biomaterials.2014; 35(26): 7610. CrossRef

15,706 View
179 Download
26 Web of Science
25 Crossref

Original Articles

The Immunoexpressions and Prognostic Significance of Inhibin Alpha and Beta Human Chorionic Gonadotrophins (hCG) in Breast Carcinomas: Eundeok Chang, Eunjung Lee, Se Jeong Oh, Jeong Soo Kim, Changsuk Kang; Cancer Res Treat. 2005;37(4):241-246. Published online August 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.4.241

Abstract PDF PubReader ePub

Purpose

Pregnancy and hCG treatments are considered essential for inhibiting breast cancer. The effect of hCG is accompanied by the synthesis of inhibin, a transforming growth factor involved in cell differentiation and proliferation. Inhibin is considered a tumor suppressor, but its role in the breast is unclear. The aim of this study was to determine the frequency and tissue distribution of the expressions of inhibin-α and β-hCG in breast cancer, and their prognostic relevance with other biological parameters.

Materials and Methods

334 of formalin-fixed, paraffin embedded tissue blocks were selected, and then immunostained for inhibin-α and β-hCG. The inhibin-α expression was compared with those of β-hCG, ER, PR and HER-2/neu, as well as the tumor characteristics and recurrences.

Results

Inhibin-α and β-hCG were expressed in 87 (26.0%) and 44 cases (13.2%), respectively. Inhibin-α was found in 25.1% of infiltrating ductal carcinomas (67/267), 26.7% of intraductal carcinomas (8/30), 33.3% of lobular tumors (3/9), 80.0% of apocrine carcinomas (4/5) and 21.7% of the other types (5/23). Inhibin-α was correlated with β-hCG (p<0.0001), PR (p=0.010) and HER-2/neu (p=0.021). HCG was focally expressed in the cytoplasm of the conventional types, but the apocrine type displayed diffusely intense cytoplasmic staining, which correlated with histological tumor types (p<0.001).

Conclusion

Inhibin was significantly correlated with the expressions of hCG, PR and HER-2/neu. Therefore, it might be a useful marker in the prevention and hormonal treatment of breast cancer, such as hCG and progesterone. HCG was expressed significantly higher in the apocrine type than the conventional types, suggesting it can be a useful adjunct in differentiating other cancer types.

Citations

Citations to this article as recorded by

Association of serum beta hCG levels in women with palpable malignant breast lesions
Ashfaque Mohammed, Talha Ahmed, Rahul R. Bhat, Esha Mallik, Aashika Arulprakasam
Scientific Reports.2023;[Epub] CrossRef
Comprehensive analysis of regulation of DNA methyltransferase isoforms in human breast tumors
Mangala Hegde, Manjunath B. Joshi
Journal of Cancer Research and Clinical Oncology.2021; 147(4): 937. CrossRef
False‐positive pregnancy test secondary to ectopic expression of human chorionic gonadotropin by a gastrointestinal stromal tumor
Neal Andruska, Lily Mahapatra, Randall Brenneman, Kelly M. MacArthur, Peter Oppelt, Brian C. Baumann
Journal of Surgical Oncology.2020; 122(4): 809. CrossRef
CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer
Yuxin Yang, Yonghong Shi, Yanjuan Hou, Ying Lu, Jinliang Yang
Cancer Medicine.2018; 7(3): 716. CrossRef
The importance of hCG in human endometrial adenocarcinoma and breast cancer
Alexandra C. Kölbl, Kristina Schlenk, Nils Behrendt, Ulrich Andergassen
The International Journal of Biological Markers.2018; 33(1): 33. CrossRef
Protective Effects of Human Chorionic Gonadotropin Against Breast Cancer: How Can We Use This Information to Prevent/Treat the Disease?
C. V. Rao
Reproductive Sciences.2017; 24(8): 1102. CrossRef
Does hCG or hCGβ play a role in cancer cell biology?
R.K. Iles, P.J. Delves, S.A. Butler
Molecular and Cellular Endocrinology.2010; 329(1-2): 62. CrossRef

8,756 View
66 Download
7 Crossref

A Clinical Analysis of PTEN Expressions in Breast Cancers: Hang Ju Cho, Jeong Soo Kim, Kee Hwan Kim, Chang Hyeok Ahn, Woo Chan Park, Se Jeong Oh, Sang Seol Jung, Keun Woo Lim, Seock Ah Im; Cancer Res Treat. 2003;35(2):102-108. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.102

Abstract PDF

PURPOSE
The PTEN gene, a novel tumor suppressor, is localized to chromosome 10q23.3 and shares extensive homology with the cytoskeletal protein, tensin. A high frequency of mutations at the PTEN locus has been described in a variety of neoplasms including breast cancer and Cowden Disease. However, the role of PTEN alterations and its association with clinicopathological factors have not been well established. We investigated the relationship between the PTEN expression and clinicopathological factors.
MATERIALS AND METHODS
Formalin-fixed, paraffin-embedded tissues from 105 women with breast cancer were evaluated for the PTEN expression and were scored semi-quantitatively based on staining intensity and distribution. Results were statistically compared with clinicopathological factors.
RESULTS
Forty-seven (45%) of the 105 breast cancers had a loss of the PTEN expression. In the recurrent group, 19 of 32 (59%) patients showed a loss of the PTEN expression, whereas in the non-recurrent group, only 28 of 73 (38%) patients showed a loss of the PTEN expression. The loss of PTEN expression correlated with estrogen receptors (ER) (p=0.027), recurrence (p=0.046), HER-2/neu overexpression (p=0.016), disease-free survival (p=0.0163), and overall survival (p=0.0357). In particular, when HER-2/ neu was overexpressed, the overall survival rate correlated with the loss of PTEN expression statistically (p=0.0454), whereas when HER-2/neu was negative, there was no correlation (p=0.9808). Progesterone receptor (PR) and disease stage had no relationship with the PTEN expression. CONCLUSION: Our results support that PTEN plays a role as a tumor suppressor in breast cancer and is a prognostic factor in predicting recurrence.

Citations

Citations to this article as recorded by

The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients
Feng Xu, Chao Zhang, Jianxiu Cui, Jun Liu, Jie Li, Hongchuan Jiang
Medicine.2017; 96(36): e8000. CrossRef

3,646 View
32 Download
1 Crossref

Clinical Analysis of PTEN, p53 and Her-2/neu Expressions in Thyroid Cancers: Jeong Soo Kim, Ja Seong Bae, Kee Hwan Kim, Chang Hyeok Ahn, Se Jeong Oh, Hae Myung Jeon, Keun Woo Lim, Chung Soo Chun; Cancer Res Treat. 2001;33(5):433-437. Published online October 31, 2001; DOI: https://doi.org/10.4143/crt.2001.33.5.433

Abstract PDF

PURPOSE
The dual-specificity phosphatase PTEN/ MMAC1/TEP1 has recently been identified as the tumor suppressor gene most frequently mutated and/or deleted in human tumors. However, PTEN mutations have rarely been detected in sporadic thyroid cancers. Therefore, this study investigated the PTEN expression of thyroid cancer and the relationship between PTEN, clinical status and other biologic factors such as HER-2/neu and p53.
MATERIALS AND METHODS
The study samples consisted of 62 thyroid cancer specimens and 24 benign thyroid tumor specimens from patients who were operated on the Department of Surgery, Uijongbu St. Mary's hospital during the 5 years from January 1995 until January 2000. All tumors were studied by immunohistochemical staining using monoclonal antibodies against PTEN, HER-2/neu and p53. The results were analyzed statistically.
RESULTS
PTEN protein was found to be under-expressed more frequently in thyroid cancers (29%) than in benign thyroid tumors (4.2%). The reduction in PTEN expression in thyroid cancers was not significantly related with the recorded clinical factors such as size, age, lymph node metastasis and p53, except for HER-2 which was found to be significantly related (p=0.001). HER-2 over- expression was noted in thyroid cancer (83.8%) more frequently than in benign tumors (16.7%).
CONCLUSION
This study has demonstrated that the under-expression of PTEN protein and the over-expression of HER-2 protein may play a role in the carcinogenesis and development of thyroid cancer.

Citations

Citations to this article as recorded by

Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions
Man Lu, Hanqing Liu, Bilian Zheng, Shengrong Sun, Chuang Chen
Cancers.2022; 14(20): 5117. CrossRef
Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome
L.A. Jonker, C.A. Lebbink, M.C.J. Jongmans, R.A.J. Nievelstein, J.H.M. Merks, E.J.M. Nieveen van Dijkum, T.P. Links, N. Hoogerbrugge, A.S.P. van Trotsenburg, H.M. van Santen
European Thyroid Journal.2020; 9(5): 234. CrossRef
Activity of Green Tea Polyphenol Epigallocatechin-3-gallate Against Ovarian Carcinoma Cell Lines
Yong Wook Kim, Su Mi Bae, Joon Mo Lee, Sung Eun Namkoong, Sei Jun Han, Byoung Rai Lee, Insu P. Lee, Sang Hee Kim, Young Joo Lee, Chong Kook Kim, Yong-Wan Kim, Woong Shick Ahn
Cancer Research and Treatment.2004; 36(5): 315. CrossRef

4,305 View
33 Download
3 Crossref

Antiangiogenesis Gene Therapy Using Adenovirus-mediated Antisense-VEGF in Glioblastoma Multiforme: Seock Ah Im, Jeong Soo Kim, Eunmi Nam, Soon Nam Lee; J Korean Cancer Assoc. 2000;32(4):764-774.

Abstract PDF: PURPOSE
Vascular endothelial growth factor (VEGF) is a major positive effector of angiogenesis. We investigated the mechanism of tumor growth inhibition by adenoviral transfer of antisense- VEGF in glioma and the role of VEGF for in vivo growth of human glioma cells according to the stage of the tumor growth.
MATERIALS AND METHODS
Replication-deficient adenoviral vector containing the VEGF cDNA in an antisense orientation (Ad5CMV-alphaVEGF) were constructed to increase the in vivo applicability of antisense sequence. The effect of Ad5CMV-alphaVEGF was studied in vitro and in vivo with human glioma cell line U-87 MG. Immunohistochemical staining of the subcutaneous tumor with anti-VEGF antibody and CD34 antibody were performed to compare VEGF protein expression and the microvessel count respectively.
RESULTS
The growth curve of U-87 MG cells treated with Ad5CMV-alphaVEGF remained as same as that of mock-infected and Ad5(dl312)-infected U-87 MG cells in vitro, suggesting that Ad5CMV-alphaVEGF does not have direct cytotoxic effect. The growth of subcutaneous human glioma xenografts was inhibited by early intratumoral injection of Ad5CMV-alphaVEGF. Immuno histochemical staining of tumors showed that VEGF protein expression and mean microvessel counts were decreased in early Ad5CMV-alphaVEGF treatment group.
CONCLUSION
The efficient down-regulation of VEGF produced by tumor cells using Ad5CMV- alphaVEGF in early stage of glioma growth has an antitumor effect in vivo through antiangiogenic mechanism.

2,347 View
15 Download

First
Prev
Page of 1
Next
Last

Search